USPTO 2015–2025 USPTO PatentsView US Corporation

Vivex Biologics Group, Inc.

USPTO PatentsView assignee record - 27 granted patents across 14 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

12.5

Avg claims per patent

+633%

5-year grant velocity

The verdict

According to USPTO PatentsView, Vivex ranks #11,513 of 50,000 tracked US assignees by granted-patent volume, with 27 patents across 14 technology areas.

#11,513
of 50,000 US assignees by volume: Top 41%
by Innovation Score (38.4/100): 12.5
avg claims per patent: +633%
grant velocity, last 5 yrs

Portfolio overview

Vivex Biologics Group, Inc. has been granted 27 US utility patents between 2019 and 2025, placing Vivex Biologics Group, Inc. at #11,513 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.5 claims per patent with primary concentration in A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;). As a US Corporation, Vivex Biologics Group, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Vivex sits between Verdesian Life Sciences U.s., Llc (27 patents, rank #11,505) and Xconnect, Llc (27 patents, rank #11,513) - the closest US assignees by grant volume. The composite Innovation Score of 38.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 22 grants, compared with 3 in the 2015–2019 window, a +633% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Vivex Biologics Group, Inc.'s 12.5 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 14 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Verdesian Life Sc…

27
Verizon Telematics

27
Vertiflex

27
Vibracoustic SE

27
Wave Computing

27
Wayne/Scott Fetzer

27
Worxsafe AB

27
Xconnect

27
Vivex Biologics G… ◀

27

What this shows Vivex holds 27 patents at rank #11,509, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Vivex

By rank, the assignees closest to #11,509 in granted patent volume.

Leaders in A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects…)

Other assignees with the most granted patents in Vivex's primary technology class.

Vivex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Vivex Biologics Group, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	3	11.1%
2020	7	25.9%
2021	3	11.1%
2022	8	29.6%
2024	4	14.8%
2025partial year	2	7.4%

Which technologies does Vivex Biologics Group, Inc. patent most?

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 19

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 14

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 9

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 8

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 5

C08L - COMPOSITIONS OF MACROMOLECULAR COMPOUNDS 3

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 2

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 2

B01F - MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING 1

B05D - PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL 1

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 1

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 1

C09D - COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR 1

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 1

Top 14 of 14 technology areas

Grant record at a glance

Portfolio Volume 27 grants

CPC subclasses 14

Avg. claims / grant 12.5

Velocity +633%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#11,513

of 50,000 tracked assignees

Innovation Score

38.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Vivex Biologics Group, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Vivex Biologics Group, Inc. ranks #11,513 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Vivex Biologics Group, Inc. hold?

Vivex Biologics Group, Inc. holds 27 US utility patents granted between 2019 and 2025, spanning 14 technology areas.

What is Vivex Biologics Group, Inc.'s Innovation Score?

Vivex Biologics Group, Inc. has an Innovation Score of 38.4 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Vivex Biologics Group, Inc. focus on?

Vivex Biologics Group, Inc.'s top technology area is A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES) with 19 patents. Grants appear in 14 CPC subclasses total.

Is Vivex Biologics Group, Inc.'s patent grant rate increasing or decreasing?

Vivex Biologics Group, Inc.'s recent grant velocity is +633% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Vivex Biologics Group, Inc.'s patents?

Vivex Biologics Group, Inc.'s patents average 12.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Vivex Biologics Group, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Vivex's 27 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Vivex ranks #11,513 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61L - see who else leads that technology area. A61L leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.